Vera Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
09 Dec 2024 //
GLOBENEWSWIRE
Vera Therapeutics Reports Inducement Grants Under Nasdaq Rule
22 Nov 2024 //
GLOBENEWSWIRE
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
18 Nov 2024 //
GLOBENEWSWIRE
Vera Therapeutics Partners with Michigan on Neptune Match & Pioneer
11 Nov 2024 //
GLOBENEWSWIRE
Vera Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
11 Nov 2024 //
GLOBENEWSWIRE
Vera Therapeutics to Participate at Upcoming Investor Conferences
08 Nov 2024 //
GLOBENEWSWIRE
Vera Therapeutics Q3 2024 Financial Results & Business Update
07 Nov 2024 //
GLOBENEWSWIRE
Vera Therapeutics Prices Public Offering of Class A Stock
29 Oct 2024 //
GLOBENEWSWIRE
Vera Therapeutics Proposes Class A Common Stock Offering
28 Oct 2024 //
#N/A
Vera Therapeutics Shows 96-Week eGFR Stabilization in IgAN
26 Oct 2024 //
GLOBENEWSWIRE
Vera Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
04 Oct 2024 //
GLOBENEWSWIRE
Vera Therapeutics Presents ORIGIN Ph 2b Results at ASN Kidney Week
02 Oct 2024 //
GLOBENEWSWIRE
Vera Therapeutics To Host R&D Day On Atacicept Expansion
16 Sep 2024 //
GLOBENEWSWIRE
Vera Therapeutics Completes ORIGIN 3 Trial Enrollment For Atacicept
12 Sep 2024 //
GLOBENEWSWIRE
Vera Therapeutics Reports Inducement Grants Under Nasdaq
10 Sep 2024 //
GLOBENEWSWIRE
Vera Therapeutics to Participate at September Investor Conferences
29 Aug 2024 //
GLOBENEWSWIRE
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 Aug 2024 //
GLOBENEWSWIRE
Vera Therapeutics Reports Q2 2024 Results And Provides Business Update
08 Aug 2024 //
GLOBENEWSWIRE
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Jul 2024 //
GLOBENEWSWIRE
Vera Therapeutics Appoints David L. Johnson As Chief Operating Officer
01 Jul 2024 //
GLOBENEWSWIRE
Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
11 Jun 2024 //
GLOBENEWSWIRE
Vera To Participate At Goldman Healthcare Conference
07 Jun 2024 //
GLOBENEWSWIRE
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Jun 2024 //
GLOBENEWSWIRE
Vera’ atacicept for treatment of IgAN receivesUS FDA breakthrough therapy desig.
30 May 2024 //
PHARMABIZ
Vera Therapeutics: FDA Breakthrough Therapy For Atacicept In IgAN
28 May 2024 //
GLOBENEWSWIRE
Vera Atacicept IgAN Phase 2b: 72-Week Egfr Hematuria Data At Era Congress
25 May 2024 //
GLOBENEWSWIRE
Vera Therapeutics Q1 2024 Results And Business Update
09 May 2024 //
GLOBENEWSWIRE
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 May 2024 //
GLOBENEWSWIRE
Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition
11 Apr 2024 //
MORNINGSTAR
Vera Announces Presentations at the 61st European Renal Association Congress
02 Apr 2024 //
GLOBENEWSWIRE
Vera Therapeutics Provides Business Update and Reports 4Q
20 Mar 2024 //
GLOBENEWSWIRE
Vera Therapeutics to Participate at 44th Annual TD Cowen Health Care Conference
28 Feb 2024 //
GLOBENEWSWIRE
Vera Therapeutics to Participate in the 6th Annual Biotechnology Conference
02 Feb 2024 //
GLOBENEWSWIRE
Vera Therapeutics Announces Closing of Upsized Public Offering
01 Feb 2024 //
GLOBENEWSWIRE
Vera Announces Pricing of Upsized Public Offering of Class A Common Stock
29 Jan 2024 //
GLOBENEWSWIRE
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
29 Jan 2024 //
PRESS RELEASE
Vera Therapeutics Presents Data Showing eGFR Stabilization in the Phase 2b Trial
25 Jan 2024 //
GLOBENEWSWIRE
Vera Therapeutics to Host In-Person R&D Day in New York
08 Jan 2024 //
GLOBENEWSWIRE
Vera Announces Appointment of Veterans Robert Brenner as CMO
08 Jan 2024 //
GLOBENEWSWIRE
Vera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
27 Dec 2023 //
GLOBENEWSWIRE
Vera Therapeutics Reports Third Quarter Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Vera Presents Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria
04 Nov 2023 //
GLOBENEWSWIRE
Vera Therapeutics Scheduled to Present at November Investor Conferences
30 Oct 2023 //
GLOBENEWSWIRE
Vera Therapeutics to Present Three Posters at the Annual Meeting
13 Oct 2023 //
GLOBENEWSWIRE
Vera Therapeutics Scheduled to Present at September Investor Conferences
31 Aug 2023 //
GLOBENEWSWIRE
Vera Provides Business Update and Reports Second Quarter Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Vera to Host Presentation of Week 36 Data from Ph2b ORIGIN Trial of Atacicept
15 Jun 2023 //
GLOBENEWSWIRE
Vera to Participate in 44th Annual Goldman Sachs Global Healthcare Conference
08 Jun 2023 //
GLOBENEWSWIRE
Vera Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Atacicept
07 Jun 2023 //
GLOBENEWSWIRE
Vera Therapeutics Reports First Quarter Financial Results
11 May 2023 //
GLOBENEWSWIRE
Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior VP
04 May 2023 //
GLOBENEWSWIRE
Vera Provides Reports Fourth Quarter and Full Year 2022 Financial Results
28 Mar 2023 //
GLOBENEWSWIRE
Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
27 Feb 2023 //
GLOBENEWSWIRE
Vera Therapeutics Announces Closing of Upsized Public Offering
06 Feb 2023 //
GLOBENEWSWIRE
Roivant, Vera seek $100M+ raises as they look to fund drug hopefuls
02 Feb 2023 //
ENDPTS
Vera Announces Commencement of Public Offering of Class A Common Stock
01 Feb 2023 //
GLOBENEWSWIRE
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
01 Feb 2023 //
GLOBENEWSWIRE
Vera Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept
30 Jan 2023 //
GLOBENEWSWIRE
Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept
25 Jan 2023 //
GLOBENEWSWIRE